King Faisal Specialist Hospital and Research Centre Utilizes Early Cancer Detection Technology for 50 Genes
RIYADH, Saudi Arabia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) has achieved a significant milestone by successfully conducting liquid biopsies on patients spanning various age groups. This innovative approach offers a safer alternative to conventional tissue biopsies. Notably, KFSH&RC stands out as the first healthcare facility in the Middle East to adopt this cutting-edge technology.
This groundbreaking method is distinguished by its ability to detect approximately 50 genes associated with cancer and over 3,000 genetic mutations. This represents a pivotal advancement in patient care, eliminating the need to extract tissue from the affected area for examination. This transformative step greatly enhances healthcare outcomes and elevates the overall patient experience.
Liquid biopsy offers advantages over traditional tissue biopsies. It's less invasive, involving a simple 10 ml blood sample that can be repeated during treatment. Additionally, it provides high accuracy in swiftly detecting tumor biomarkers, predicting treatment responses, identifying emerging mutations, and confirming the absence of tumor recurrence, marking a significant advancement in cancer science.
This technology presents a safer alternative to traditional biopsies for patients facing challenges in accessing affected tissue without surgical intervention, as seen in cases like lung cancer. It is particularly beneficial for elderly patients, for whom a lung tissue biopsy may not be suitable due to the potential for severe complications associated with it.
As a strategic health partner at the Global Health Exhibition in Riyadh from October 29 to 31, KFSH&RC will showcase its pavilion in the accompanying exhibition, where visitors can explore Liquid biopsy technology and various other healthcare solutions and technologies.
Liquid biopsy technology holds promise for other stages of cancer treatment at KFSH&RC. Through the routine use of the test, it is possible to build a database of tumor-causing mutations in the local community, which helps in early diagnosis of cancer before tumors form, in addition to tracking changes in the patient’s condition, frequently during treatment, allowing timely adjustments to treatment plans and preventing worsening of the condition.
This achievement is a part of KFSH&RC's ongoing commitment to harness advanced technologies for enhancing operational excellence and patient care. The test facilitates swift clinical decision-making for cancer patient management and reduces both the testing time and its process through full automation.
KFSH&RC stands as one of the world's prominent institutions in delivering specialized healthcare, leading the way in innovation, and serving as an advanced hub for medical research and education. Furthermore, it actively endeavors to advance medical technologies and elevate global healthcare standards through collaborations with significant local, regional, and international organizations, aiming to deliver world-class clinical, research, and educational services.
Photos accompanying this announcement are available at:To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Innofactor Plc: Share Repurchase 11.12.202311.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 11.12.2023Innofactor Plc: Share Repurchase 11.12.2023In the Helsinki Stock ExchangeTrade date 11.12.2023Bourse trade BuyShare IFA1VAmount 4,300SharesAverage price/ share 1.1599EURTotal cost 4,987.57EURInnofactor Plc now holds a total of 584 329 sharesincluding the shares repurchased on 11.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 firstname.lastname@example.org Attachment Innofactor_11.12_trades
Mandatory notification of trade and acceptance by primary insiders11.12.2023 17:12:12 CET | Press release
Reference is made to the stock exchange announcement on 7 December 2023 whereby BW Sirocco Holdings AS (the "Offeror") announced the completion and settlement of the Offer and the acquisition of the Offeror of 30,000,561 shares, representing approximately 95.21% of the total number of shares in BW Ideol AS. The Offeror, being a close associate of Marco Beenen, the chairperson of the board of directors of BW Ideol AS, attach the required notifications of trade to this announcement. Further, mandatory notifications from other primary insiders and their related parties are also attached to this announcement. For further information, please contact: BW Ideol AS Nicolas de Kerangal (Chief Financial & Partnerships Officer) +33 (0) 7 76 87 70 08 / email@example.com (mailto:firstname.lastname@example.org) BW Sirocco Holdings AS Anders S. Platou (Chief Strategy Officer BW Offshore Limited) +47 99 71 86 55 Attachment Project Sirocco - PDMR - Attachments
LambdaTest and Wipro Collaborate for Innovative Gen AI Solutions11.12.2023 17:00:00 CET | Press release
LambdaTest and Wipro forge a pioneering partnership, integrating Wipro’s Gen AI-powered QE capabilities with LambdaTest’s HyperExecute, to revolutionize software testing on the Cloud with advanced AI capabilities. San Francisco , Dec. 11, 2023 (GLOBE NEWSWIRE) -- LambdaTest, a leading cloud-based unified testing platform is partnering with Wipro Limited, a leading technology services and consulting company, to revolutionize software testing by integrating Wipro’s Gen AI powered QE platform IntelliAssure with HyperExecute - a continuous cloud test orchestration solution offered by Lambdatest. The partnership aims to provide organizations that are modernizing and migrating to the cloud with an easy-to-implement, plug-and-play solution for infusing analytics-driven intelligence across their testing lifecycle for improved productivity as well as hyper-accelerated release cycle times. LambdaTest and Wipro's collaborative integration promises cutting-edge capabilities with an aim to enrich t
Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub11.12.2023 16:30:00 CET | Press release
Press Release Nokia unveils plans for new state-of-the-art research and development facility for Nokia Bell Labs in New Brunswick, New Jersey technology hub Nokia Bell Labs is reaffirming its commitment to New Jersey, upholding its 80-year heritage of cutting-edge research and innovation in the state.Move will establish New Brunswick as Nokia’s new R&D hub on the East Coast and affirms Nokia’s commitment to this fast-growing innovation zone in the US. 11 December 2023 New Brunswick, New Jersey – Nokia today announced plans to relocate its campus in Murray Hill, NJ by 2028 to a new state-of-the-art research and development (R&D) facility in the burgeoning innovation and technology hub in New Brunswick, NJ. The new leading-edge R&D facility will propel Nokia Bell Labs to adapt and evolve to remain at the forefront of cutting-edge technology and continue contributing to a legacy of innovation in New Jersey. As the industrial research arm of Nokia, Nokia Bell Labs has always moved ahead of
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties11.12.2023 16:30:00 CET | Press release
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties Pursuant to article 19 of the EU Regulation 596/2014 and according to a power of attorney given by Anne Mette Toftegaard, Alm. Brand A/S is required to file information on trading in shares in Alm. Brand A/S or other securities related to these shares by executives and their related parties. Please see attached report. Contact Please direct any questions regarding this announcement to: Senior Investor Relations Officer Mikael Bo Larsen, Mobile no. +45 51 43 80 02 Attachment AS 26 2023 - Report on trading Anne Mette Toftegaard